Alivus Life — 360° view

Alivus Life, a company in the Pharmaceuticals industry, reported revenue of ₹682 crore and net profit of ₹197 crore for the September 2026 quarter.

Alivus Life (NSE: ALIVUS) closed at ₹1,436.90 on 20 Nov 2026, up 57.9% over the past year. Its market capitalisation is ₹17,669 crore and it trades at 25.7 times earnings.

Share price
₹1,436.90 (20 Nov 2026)
Market cap
₹17,669 Cr (20 Nov 2026)
P/E
25.67 (20 Nov 2026)
Revenue
₹682 Cr (September 2026 quarter)
Net profit
₹197 Cr (September 2026 quarter)
ROCE
23.8% (FY26)
ROE
18.1% (FY26)
Book value
₹296 (FY26)
Dividend yield
0.35% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,574.00 / ₹819.00 (20 Nov 2026)
1-year return
57.9% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: ALIVUS

Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.